iPSC Cell Therapy

End-to-End Platform Overview

Full Integration Under One Roof

Evotec provides all relevant technologies and infrastructure, in addition to broad expertise and an experienced scientific team, to jump start and speed-up the development of a new class of cell therapies with the potential to cure multiple diseases. This involves all steps from research to development up to clinical testing of cell therapy product candidates in patients. Thus, it comprises an end-to-end integrated process flow from project inception to the clinic, including cell differentiation, upscaling, GMP gene editing and manufacturing.

In addition to manufacturing clinical material, Evotec, through its teams at the Modena and Verona sites, provides regulatory support from the development phase up to market entry, as well as clinical CRO services.

End to End Platform Integrated Under One Roof Platform Overview

Gene Editing Process for Targeted Engineering

We have a process in place for highly efficient nuclease-based gene editing at the iPSC stage. This includes a quality control (QC) workflow with specific protocols, e.g., extensive genetic testing, to ensure genomic integrity, prior to selecting an iPSC clone for master cell bank (MCB) generation.

Gene editing can also be performed in a GMP environment and in a GMP compliant manner.

Ipsc Cell Therapy Platform Overview Gene Editing Process

Immune Cloaking & FailSafe as Key Enabling Technologies

To create safe, immune-compatible iPSC-derived cell therapy products, we utilize in-licensed and proprietary state-of-the-art methods. Immune cloaking technology blocks the response pathways for key immune cells thus allowing the use of off-the-shelf cell products without immunosuppression.

As an additional safety feature, we can apply Fail-SafeTM technology (licensed from panCELLa)- a drug-inducible kill switch allowing to selectively eliminate unwanted dividing cells.

iPSC Cell Therapy Platform Overview Cloaked Beta Cells

State-of-the-Art GMP Manufacturing

Evotec’s Modena site serves as a center of excellence for cell therapy manufacturing. The facility specializes in state-of-the-art cGMP manufacturing, including the production of clinical material for iPSC-derived therapies and other allogeneic and autologous therapies such as MSCs, TILs, CAR-T cells, and dendritic cells. The site offers pre-GMP development, optimization, technology transfer, and full regulatory support. Additionally, the facility is equipped to perform GMP-compliant complex gene editing steps and generate cell banks, including clonal banks. Evotec’s end-to-end development capabilities are complemented by support for GLP studies, Tox-batch manufacturing, and integration with the certified clinical CRO at their Verona site.


Meet Our Experts

Headshot Andreas Scheel
Evotec logo big

Andreas Scheel, PhD

EVP, Head of Cell Therapy & Site Head Cologne

Evotec logo big

Latest update: July 2024


Andreas Scheel, as the EVP Head of Cell Therapy, leads the focus area “iPSC-based Cell Therapies” at Evotec. He also serves as the site head of the Cologne facility and is responsible for the cell therapy core teams located in Göttingen and Cologne.

In his role, Andreas is primarily responsible for the strategic development of this focus area together with a leadership team and for the establishment of strategic partnerships. He ensures the teams have the required expertise and fosters a cohesive identity across different sites. Andreas actively engages in internal networking and garners management support to promote transparency as this field continues to grow within the company. Additionally, he provides vital support to specific projects.

Andreas and his team's work holds immense importance, as they develop novel therapies to address urgent patient needs, striving to cure (rather than just treat) specific diseases with the unique advantages of iPSC-based cell therapy. At Evotec, Andreas values the company's commitment to investing in promising areas, granting senior leaders like himself the autonomy to define strategies. The dynamic and diverse environment at Evotec, with its vast expertise and multicultural teams, allows Andreas to excel in developing innovative platforms that have the potential to revolutionize medical treatments. His dedication and leadership position him as an invaluable asset in Evotec's pursuit of groundbreaking therapies.

Interest and Experience

Apart from his professional achievements, Andreas finds joy and fulfillment in his family and sports. He thrives in fast-paced environments and embraces challenging situations, making critical decisions with urgency, which allows him to tap into his creativity and excel in his work at Evotec.

Evotec logo big
Headshot of Christine Guenther
Evotec logo big

Christine Guenther

EVP, Head of Global Cell Therapy Translation & Site Head Modena

Evotec logo big

Latest update: July 2024


Christine is a seasoned executive in the development, manufacturing and translation of Cell Therapies from early stage through clinical development until market reach in Europe. She joined Evotec International GmbH in 2021 as Executive Vice President, Head of Global Cell Therapy Translation & Medical Director. Recently she was appointed as Site Head of Evotec´s Cell Manufacturing site in Modena (IT). Her focus is the integrated development of cell therapy and the building of partnerships with Pharma/ Biotech.

Christine brings more than 30 years of experience in clinical and translational Cell Therapy, both in the allogeneic and autologous field, complemented by the iPSC-focus at Evotec. From 2008 to 2020 she served as CEO and Medical Director at Apceth, Cell & Gene therapy (Munich, GER, now Minaris Regenerative Medicine) building the Biotech from start-up to a profitable CDMO and research company. The company developed the worldwide first clinical study with genetically modified stem cells (MSC). Apceth was acquired by Hitachi Chemical in 2019 and integrated into a global CDMO network. Prior to that she served as Medical Director and Qualified Person at a non-profit organization for stem cell donation and cord blood transplantation.

Christine has a strong medical background as Senior Hematologist/ Oncologist working in academic Hospitals and the University Hospital in Munich with a focus on hematologic stem cell transplantation and adoptive cell therapy (1988-2002).

She holds a medical license from University of Munich and performed her PhD in experimental Hematology at the Helmholtz Society (Munich). She worked over 10 years as certified Qualified Person, and contributed in task forces and associations to the progress of Cell Therapy.

Evotec logo big